BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

24 Oct 2022 06:00:00 By Nasdaq GlobeNewswire

BioCryst to Report Third Quarter 2022 Financial Results on November 1

18 Oct 2022 06:00:39 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Oct 2022 06:00:45 By Nasdaq GlobeNewswire

BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer

14 Sep 2022 15:01:10 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Sep 2022 06:00:52 By Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

31 Aug 2022 15:01:59 By Nasdaq GlobeNewswire

FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

31 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients

26 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness

25 Aug 2022 06:00:14 By Nasdaq GlobeNewswire

BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia

18 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones

04 Aug 2022 06:00:24 By Nasdaq GlobeNewswire

BioCryst Resumes Enrollment in BCX9930 Clinical Program

04 Aug 2022 05:58:25 By Nasdaq GlobeNewswire

BioCryst to Report Second Quarter 2022 Financial Results on August 4

21 Jul 2022 06:00:44 By Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conference

15 Jul 2022 06:00:23 By Nasdaq GlobeNewswire

BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)

01 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022

22 Jun 2022 06:00:02 By Nasdaq GlobeNewswire

BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America

09 Jun 2022 06:00:00 By Nasdaq GlobeNewswire

FDA Grants Fast Track Designation for BioCryst’s ALK-2 Inhibitor, BCX9250

08 Jun 2022 06:00:01 By Nasdaq GlobeNewswire

BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic

07 Jun 2022 08:00:02 By Nasdaq GlobeNewswire

BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks

06 Jun 2022 06:00:30 By Nasdaq GlobeNewswire